Basel, August 2, 2017 – BaÅkent University’s hospital cluster is joining the Patient Recruitment System platform, giving their 4.5 M patients access to treatments and therapies offered by clinical research.
BaÅkent University has its headquarters in Ankara, Turkey. With over 1,500 beds, the university has hospitals in seven further locations throughout Turkey. There are six general hospitals, in Ankara, Adana, Alanya, İstanbul, Konya, and İzmir; and four specialist centers: the AyaÅ Physical Therapy and Rehabilitation Center, the Yapracık Psico-Social Rehabilitation Center, Umitkoy Polyclinic, and another eight geographically distributed dialysis centers.
With this move, BaÅkent University will gain the advantages of partnership with the Patient Recruitment System (PRS) platform: visibility to sponsors making trial siting decisions, increased speed and effectiveness in recruitment, increased efficiency in matching studies to the hospital’s own patient population. Sites can also make use of PRS, internally, for academic trials with the assurance of compliance to hospital-level data access permissions.
The addition of BaÅkent University extends Clinerion’s coverage, geographically, throughout Turkey. It also extends the PRS network’s treatment capabilities with the addition of specialist centers for physical and psychological rehabilitation, and dialysis.
“BaÅkent University is proud to be the premier private medical research institution in Turkey and we are happy that partnership with Clinerion will also allow us to increase participation in the international research and development of the next generation of medical treatments,” says Professor Haldun MüderrisoÄlu, Dean of the Medical Faculty at BaÅkent University. “This will also allow us to offer more treatment options for our patients.”
“We are very happy to have the best private university hospital group in Turkey in PRS,” says Ulf Claesson, CEO of Clinerion. “We have been expanding around the world, but BaÅkent allows us to extend our presence throughout Turkey, giving us near-complete coverage of the country.”
Contact details for Clinerion Turkey:
BariÅ ErdoÄan, PhD
Head of EEMEA Region
Clinerion Turkey Teknoloji Arastirma Ltd. Sti.
Uphill Towers A-87 Batı, AtaÅehir, İstanbul, Türkiye
T +90 216 688 00 86
Clinerion website: www.clinerion.com
Clinerion’s Patient Recruitment System: www.clinerion.com/index/OverviewOurSolutions/PatientRecruitmentSystem
For more information, please contact:
Le Vin Chin
Head of Marketing and Communications
Clinerion Ltd
Margarethenstrasse 47, CH-4053 Basel, Switzerland
Tel.: +41 61 865 60 54
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.